

William J Taranto



President, Merck Global Health Innovation Fund LLC

Bill Taranto is President, Merck Global Health Innovation Fund LLC (GHIF). Mr. Taranto is the founder of GHI and is responsible for leading the GHI capability for Merck. The Merck Global Health Innovation Fund was established in late 2010 as a strategic response to the challenges surrounding Merck's core business of discovering, developing and marketing innovative drugs and vaccines.

GHI deploys its evergreen \$500 million fund focused on identifying opportunities that are adjacent to Merck's core business of pharmaceuticals and vaccines. In the last thirteen years, GHI has committed over \$1 Billion across 70 portfolio companies. Some investments include PathAI, M2GEN, Navigating Cancer, Syapse, Strata, Precise DX, and Trinetx. Recent Unicorn exits include Livongo Health, Preventice Solutions, Ciox and Absci.

Mr. Taranto recently was Chairman of the Board, Preventice Solutions Inc., prior Board Member Livongo Health, Advisory Board Member Global Corporate Venturing and Advisory Board Member Health XL and Chairman, Advisory Board to Columbia HITLAB. .